New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
06:33 EDTAVEOAveo, Astellas announce initiation of patient enrollment in tivozanib trial
AVEO Oncology and Astellas Pharma announced the initiation of patient enrollment in a randomized, double-blind, multicenter Phase 2 clinical trial, called BATON-BC, evaluating the efficacy of tivozanib, an investigational drug, in combination with paclitaxel compared to placebo in combination with paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer who have received no prior systemic therapy for advanced or metastatic breast cancer. Triple negative breast cancer was selected for tivozanib clinical evaluation because of high unmet need and insights gained from AVEO's Human Response PlatformTM indicating that these tumors are enriched for a signature of VEGF pathway deregulation similar to that seen in renal cell carcinoma.
News For AVEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 13, 2015
07:04 EDTAVEOAveo Pharmaceuticals estimates Q4 cash, securities of $52M
Aveo Pharmaceuticals in conference presentation slides estimates its Q4 cash and securities at around $52M. Aveo said its streamlined operations by exiting a long term facilities lease and eliminating research functions. It cut its headcount from 60 to 20, which it expects to reduce annual compensation expenses by $6M. The company said it will reduce facilities requirements by up to 80% of its current space, including the elimination of lab and vivarium needs.
January 12, 2015
07:17 EDTAVEOJPMorgan to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use